Is timing everything? A meeting report of the society for women's health research roundtable on menopausal hormone therapy

Journal of Women's Health

Volumn 22, Issue 4, 2013, Pages 303-311

  Davies, Erika ^a   Mangongi, Ngoda P ^b   Carter, Christine L ^a  

^a Society for Women's Health Research   (United States)

^b AMERICAN INSTITUTES FOR RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE;

AGING; ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; MEDICAL SOCIETY; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION;

ADVISORY COMMITTEES; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH CARE REFORM; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; PRACTICE GUIDELINES AS TOPIC; RESEARCH REPORT; RISK FACTORS; SOCIETIES, MEDICAL; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 84876223268     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2013.4386     Document Type: Article

References (64)

1. Manson JE, Bassuk SS. The menopause transition and postmenopausal hormone therapy. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2008:2334-2339.
2. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390.
3. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dys-phoric disorder. Am J Psychiatry 2004;161:343-351.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
6. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
7. Anderson GL, Limacher M, Assaf AR, et al. Effects of con-jugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
8. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. ARHQ Publications, Rockville, MD, Number 12-05168-EF-2. 2013.
9. Moyer VA. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
10. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: Results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120:595-603.
11. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of cor-onary artery atherosclerosis by 17-beta estradiol in ovariec-tomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-1057.
12. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
13. Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: A review. Maturitas 1990;12: 259-285.
14. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the pre-vention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
15. Steiner AZ, Xiang M, Mack WJ, et al. Unopposed estradiol therapy in postmenopausal women: Results from two ran-domized trials. Obstet Gynecol 2007;109:581-587.
16. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hor-mone therapy: Past, present and future in perspective. Cli-macteric 2012;15:217-228.
17. Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: Cardiovascular events associated with nonsteroidal anti-in-flammatory drugs. Am J Med 2006;119:552-559.
18. Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: Its origin, current status, and future. Menopause 2013;20:342-353.
19. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
20. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ 345:e6409.
21. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-2434.
22. Benavides-Piccione R, Fernaud-Espinosa I, Robles V, Yuste R, Defelipe J. Age-based comparison of human dendritic spine structure using complete three-dimensional recon-structions. Cereb Cortex 2012 [Epub ahead of print].
23. Hara Y, Park CS, Janssen WG, Punsoni M, Rapp PR, Morrison JH. Synaptic characteristics of dentate gyrus axonal boutons and their relationships with aging, menopause, and memory in female rhesus monkeys. J Neurosci 2011;31:7737-7744.
24. Morrison JH, Baxter MG. The ageing cortical synapse: Hall-marks and implications for cognitive decline. Nat Rev Neu-rosci 2012;13:240-250.
25. Keller JN, Germeyer A, Begley JG, Mattson MP. 17Beta-es-tradiol attenuates oxidative impairment of synaptic Na + / K + -ATPase activity, glucose transport, and glutamate trans-port induced by amyloid beta-peptide and iron. J Neurosci Res 1997;50:522-530.
26. Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging 2012;33:1129-1137.
27. Khoo SK, O'Neill S, Byrne G, King R, Travers C, Tripcony L. Postmenopausal hormone therapy and cognition: Effects of timing and treatment type. Climacteric 2010;13:259-264.
28. Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study. Neurology 2009;73:1729-1737.
29. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive per-formance in midlife women. Neurology 2009;72:1850-1857
30. Rasgon NL, Magnusson C, Johansson AL, Pedersen NL, Elman S, Gatz M. Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: A preliminary study. Psychoneuroendocrinology 2005;30: 558-567.
31. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: The REMEMBER pilot study. Meno-pause 2006;13:28-36.
32. Henderson VW, Popat RA. Effects of endogenous and ex-ogenous estrogen exposures in midlife and late-life women on episodic memory and executive functions. Neuroscience 2011;191:129-138.
33. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
34. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2651-2662.
35. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant infer-ences from observational and experimental research. Neu-roscience 2006;138:1031-1039.
36. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: The critical window theory revisited. Ann Neurol 2011;69:163-169.
37. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study. Neurology 2012;79:1846-1852.
38. Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women's Health Across the Nation (SWAN). J Bone Miner Res 2012;27:111-118.
39. Rencken ML, Chesnut CH 3rd, Drinkwater BL. Bone density at multiple skeletal sites in amenorrheic athletes. JAMA 1996;276:238-240.
40. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276:1389-1396.
41. Gallagher JC, Kable WT, Goldgar D. Effect of progestin ther-apy on cortical and trabecular bone: Comparison with estro-gen. Am J Med 1991;90:171-178.
42. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and with-out medroxyprogesterone acetate on bone in early post-menopausal women. JAMA 2002;287:2668-2676.
43. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women un-der 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-492.
44. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003; 290:1729-1738.
45. Gallagher JC, Rapuri PB, Haynatzki G, Detter Jr. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002;87:4914-4923.
46. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
47. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health out-comes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A ran-domized controlled trial. JAMA 2011;305:1305-1314.
48. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: Results from a prospective study in a large health management organization. Meno-pause 2011;18:1172-1177.
49. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: A randomized, double-blind, multicenter trial. Menopause 2005;12:716-727
50. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmen-opausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591-597
51. Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: Rando-mised controlled trial. BMJ 2008;337:a1190.
52. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is as-sociated with better health-related quality of life in post-menopausal women, as measured by the generic 15D instrument. J Br Menopause Soc 2005;11:145-151.
53. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effec-tiveness of hormone therapy in younger and older postmen-opausal women. Am J Med 2009;122:42-52 e42.
54. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hor-mones and breast cancer in postmenopausal women: Re-analysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606-616.
55. Group IW. IARC Monographs on the Evaluation of Car-cionogenic Risks to Humans. International Agency for Re-search on Cancer 1999;72:660.
56. Group IW. IARC Monographs on the Evaluation of Carci-nogenic Risks to Humans. International Agency for Research on Cancer 2007;91:528.
57. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus proges-tin. Maturitas 2006;55:103-115.
58. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
59. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mam-mography screening in postmenopausal women with hys-terectomy. JAMA 2006;295:1647-1657.
60. Beral V, Bull D, Green J, Reeves G Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369:1703-1710.
61. Fernandez E, La Vecchia C, Braga C, et al. Hormone re-placement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998;7:329-333.
62. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705-712.
63. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067-1071.
64. Prihartono N, Palmer JR, Louik C, Shapiro S, Rosenberg L. A case-control study of use of postmenopausal female hor-mone supplements in relation to the risk of large bowel cancer. Cancer Epidemiol Biomarkers Prev 2000;9:443-447.